TLTFF Stock - Theralase Technologies Inc.
Unlock GoAI Insights for TLTFF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.03M | $1.07M | $1.14M | $780,641 | $929,122 |
| Gross Profit | $554,026 | $562,134 | $628,174 | $309,943 | $269,680 |
| Gross Margin | 53.6% | 52.5% | 55.2% | 39.7% | 29.0% |
| Operating Income | $-4,288,350 | $-4,594,266 | $-5,231,544 | $-4,541,543 | $-5,593,020 |
| Net Income | $-4,256,114 | $-4,570,879 | $-5,235,302 | $-4,411,061 | $-5,598,540 |
| Net Margin | -411.8% | -427.1% | -459.8% | -565.1% | -602.6% |
| EPS | $-0.02 | $-0.02 | $-0.03 | $-0.02 | $-0.03 |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.
Visit WebsiteEarnings History & Surprises
TLTFFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 27, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.00 | $-0.00 | -29.6% | ✗ MISS |
Q3 2025 | Aug 26, 2025 | $-0.00 | $-0.00 | -27.7% | ✗ MISS |
Q2 2025 | May 30, 2025 | $-0.00 | $-0.00 | -100.5% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-0.00 | $-0.00 | -27.9% | ✗ MISS |
Q4 2024 | Nov 27, 2024 | $-0.00 | $-0.00 | -49.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.00 | $-0.00 | -48.5% | ✗ MISS |
Q2 2024 | May 30, 2024 | — | $-0.00 | — | — |
Q1 2024 | Mar 27, 2024 | — | $-0.00 | — | — |
Q4 2023 | Nov 29, 2023 | $-0.01 | $-0.00 | +53.3% | ✓ BEAT |
Q3 2023 | Aug 29, 2023 | $-0.01 | $-0.00 | +46.6% | ✓ BEAT |
Q2 2023 | May 30, 2023 | $-0.01 | $-0.00 | +34.9% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q4 2022 | Nov 29, 2022 | $-0.01 | $-0.01 | -40.1% | ✗ MISS |
Q3 2022 | Aug 29, 2022 | $-0.01 | $-0.01 | -40.1% | ✗ MISS |
Q2 2022 | May 30, 2022 | $-0.01 | $-0.01 | +16.6% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $-0.01 | $-0.01 | -49.9% | ✗ MISS |
Q4 2021 | Nov 29, 2021 | $-0.01 | $-0.01 | 0.0% | = MET |
Q3 2021 | Aug 30, 2021 | $-0.01 | $-0.01 | -40.1% | ✗ MISS |
Latest News
Frequently Asked Questions about TLTFF
What is TLTFF's current stock price?
What is the analyst price target for TLTFF?
What sector is Theralase Technologies Inc. in?
What is TLTFF's market cap?
Does TLTFF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TLTFF for comparison